HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Toshiyuki Aramaki Selected Research

tocilizumab (atlizumab)

11/2017Tocilizumab is effective in a familial Mediterranean fever patient complicated with histologically proven recurrent fasciitis and myositis.
9/2016Rapid improvement of Clinical Disease Activity Index (CDAI) at 3 months predicts a preferable CDAI outcome at 1 year in active rheumatoid arthritis patients treated with tocilizumab: results from an observational investigation of daily clinical practice.
9/2016Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis.
8/2011Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.
8/2011In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline.
4/2011Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis.
2/2010Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Toshiyuki Aramaki Research Topics

Disease

34Rheumatoid Arthritis
09/2023 - 01/2006
6Synovitis
09/2022 - 11/2007
4Edema (Dropsy)
09/2022 - 11/2007
3Infections
10/2023 - 01/2017
3Arthritis (Polyarthritis)
01/2023 - 06/2009
2Systemic Lupus Erythematosus (Libman-Sacks Disease)
05/2024 - 01/2010
2Neoplasms (Cancer)
10/2023 - 08/2012
2Herpes Zoster
10/2023 - 01/2017
2Autoimmune Diseases (Autoimmune Disease)
06/2023 - 01/2023
2Fever (Fevers)
06/2023 - 08/2012
2Vasculitis (Vasculitides)
06/2023 - 11/2020
2Rheumatic Diseases (Rheumatism)
09/2022 - 05/2019
2Hemorrhage
12/2011 - 06/2009
2Tropical Spastic Paraparesis (Tropical Spastic Paraplegia)
01/2009 - 01/2008
1Communicable Diseases (Infectious Diseases)
10/2023
1Lipoma (Lipomata)
09/2023
1Urticaria (Hives)
06/2023
1Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome)
06/2023
1Arthralgia (Joint Pain)
06/2023
1Exanthema (Rash)
06/2023
1Purpura
06/2023
1Cardiovascular Diseases (Cardiovascular Disease)
09/2022
1Immunoglobulin G4-Related Disease
01/2022
1T-Cell Leukemia (Leukemia, T Cell)
09/2021
1Sarcoidosis (Schaumann Disease)
11/2020
1Osteoporosis
05/2019
1HTLV-I Infections (HTLV-I Infection)
01/2018
1Fasciitis (Fascitis)
11/2017
1Familial Mediterranean Fever (Periodic Disease)
11/2017
1Myositis (Idiopathic Inflammatory Myopathies)
11/2017
1Takayasu Arteritis (Arteritis, Takayasu's)
12/2016
1Cryoglobulinemia
09/2013
1Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)
12/2011
1Pyelonephritis
12/2011
1Urinary Tract Infections (Urinary Tract Infection)
12/2011
1Disseminated Intravascular Coagulation
12/2011
1Thrombocytopenia (Thrombopenia)
12/2011
1Sepsis (Septicemia)
12/2011
1Myocarditis (Carditis)
12/2010
1Vascular Skin Diseases
02/2010
1Necrosis
02/2010

Drug/Important Bio-Agent (IBA)

8Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
09/2023 - 07/2009
7Tumor Necrosis Factor InhibitorsIBA
10/2023 - 02/2010
7tocilizumab (atlizumab)FDA Link
11/2017 - 02/2010
5Antirheumatic Agents (DMARD)IBA
01/2020 - 04/2012
5Anti-Citrullinated Protein AntibodiesIBA
01/2017 - 01/2006
5Rheumatoid FactorIBA
09/2013 - 01/2006
4Immunoglobulin M (IgM)IBA
08/2011 - 01/2006
4Etanercept (Enbrel)FDA Link
06/2011 - 01/2009
3tofacitinibIBA
10/2023 - 01/2017
3GadoliniumIBA
09/2012 - 06/2009
3cyclic citrullinated peptideIBA
06/2009 - 01/2006
2GlucocorticoidsIBA
10/2023 - 05/2019
2baricitinibIBA
10/2023 - 01/2021
2Interleukin-6 (Interleukin 6)IBA
09/2023 - 11/2007
2VaccinesIBA
06/2023 - 01/2023
2Adrenal Cortex Hormones (Corticosteroids)IBA
09/2022 - 08/2012
2Biomarkers (Surrogate Marker)IBA
07/2021 - 06/2021
2Abatacept (Orencia)FDA Link
07/2021 - 06/2021
2Antineutrophil Cytoplasmic Antibodies (ANCA)IBA
11/2020 - 06/2009
2Infliximab (Remicade)FDA Link
12/2018 - 02/2010
2Matrix Metalloproteinase 3 (Stromelysin 1)IBA
08/2012 - 11/2007
2Prednisolone (Predate)FDA LinkGeneric
12/2010 - 01/2010
2mizoribineIBA
12/2010 - 01/2010
2Cartilage Oligomeric Matrix ProteinIBA
10/2010 - 06/2009
2AutoantibodiesIBA
01/2010 - 06/2009
2AntibodiesIBA
06/2009 - 01/2009
2C-Reactive ProteinIBA
06/2009 - 11/2007
1belimumabIBA
05/2024
1anifrolumabIBA
05/2024
1Janus Kinase InhibitorsIBA
10/2023
1CytokinesIBA
09/2023
12019-nCoV Vaccine mRNA-1273IBA
06/2023
1Messenger RNA (mRNA)IBA
06/2023
1mRNA VaccinesIBA
01/2023
1SteroidsIBA
09/2022
1Immunoglobulin G (IgG)IBA
01/2022
1Complement System Proteins (Complement)IBA
01/2022
1ametantrone (HAQ)IBA
11/2020
116S Ribosomal RNAIBA
11/2020
1Methotrexate (Mexate)FDA LinkGeneric
01/2020
1DenosumabFDA Link
05/2019
1Interleukin-17 (Interleukin 17)IBA
12/2016
1Gadolinium DTPA (Magnevist)FDA Link
09/2012
1Pentetic Acid (DTPA)FDA LinkGeneric
09/2012
1Adalimumab (Humira)FDA Link
02/2012
1EndotoxinsIBA
12/2011
1Anti-Bacterial Agents (Antibiotics)IBA
12/2011
1Inosine Triphosphate (ITP)IBA
12/2011
1ThrombomodulinIBA
12/2011
1Dacarbazine (DIC)FDA LinkGeneric
12/2011
1fibrin fragment D (D-dimer)IBA
12/2011
1amsonic acid (DAS)IBA
08/2011
1Substance PIBA
06/2011
1LipidsIBA
04/2011
1AcidsIBA
03/2011

Therapy/Procedure

8Therapeutics
06/2023 - 01/2007
2Remission Induction
08/2011 - 01/2009
1Treatment Delay
04/2012
1Platelet Transfusion (Blood Platelet Transfusions)
12/2011